Yuanta Investment, which will launch one of two major new public/private biopharma support funds in South Korea later this year, talks about the strategy behind the initiative and the plans for diverse collaborations with pharma companies both at home and abroad.

Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.

The Pink Sheet’s roundup of key regulatory issues in Korea for 2022 and outlook for this year.

Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.